Paper Details

  1. Home
  2. Paper Details

Evaluation of Current and Emerging Antimalarial Medicines for Inhibition of Toxoplasma gondii Growth in Vitro.

Author: BurrowsJeremy N, GoldbergDaniel E, RadkeJoshua B, SibleyL David

Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study evaluated the potential of antimalarial drugs for treating toxoplasmosis. Most antimalarial compounds had limited efficacy against T. gondii tachyzoites, suggesting that many essential processes targeted by antimalarials in Plasmodium spp. are either divergent or nonessential in T. gondii.
Paper Details　
Original Abstract of the Article :
Toxoplasma gondii is a common zoonotic infection of humans, and estimates indicate that 1-2 billion people are chronically infected. Although largely asymptomatic, chronic infection poses risk of serious disease due to reactivation should immunity decline. Current therapies for toxoplasmosis only co...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/29998728

データ提供：米国国立医学図書館（NLM）

Evaluating Antimalarial Medicines for Toxoplasmosis Treatment

Toxoplasmosis is a widespread parasitic infection that can cause serious health issues. Currently, there are limited treatment options that only control acute infection and don't target the chronic tissue cyst stages. This study evaluated the potential of existing and emerging antimalarial drugs for treating toxoplasmosis, exploring whether they could also be effective against this parasitic infection.

Limited Repurposing Potential of Antimalarial Drugs

Surprisingly, the majority of antimalarial compounds showed limited effectiveness in inhibiting the growth of T. gondii tachyzoites. This suggests that many essential processes targeted by antimalarial drugs in the malaria parasite are either different or not essential in T. gondii.

Challenges in Repurposing Antimalarial Drugs for Toxoplasmosis

This research highlights the challenges in repurposing antimalarial drugs for toxoplasmosis treatment. It's like finding that the oasis we thought would quench our thirst for a new treatment is actually a mirage. The study emphasizes the need to explore novel approaches to treating toxoplasmosis, particularly for eradicating the chronic cyst stages.

Dr. Camel's Conclusion

While the study's findings may seem discouraging, they provide valuable insights into the differences between malaria and toxoplasmosis. It underscores the importance of developing new treatments specifically for toxoplasmosis, which may require a more focused approach to target the parasite's unique characteristics.

Date :
  1. Date Completed 2019-10-17
  2. Date Revised 2019-10-17
Further Info :

Pubmed ID

29998728

DOI: Digital Object Identifier

NIHMS983845

Related Literature

Article Analysis
・Side Effects of sulfadiazine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.